pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

5,200 stories · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1605Endpoints1257BioSpace587Fierce Biotech585BioPharma Dive474raps199onclive165fda recalls105fda medwatch
therapy area
allOncology10896Rare Disease2804Immunology2568Cardiology2301Pulmonology1918Hematology1909Vaccines1659Psychiatry & CNS1111
  • Corsera wins Endpoints 11 2026 award, marking a major bet by veteran biotech leaders Meanwell and Maraganore
    Corsera was announced as the winner of the Endpoints 11 2026 competition, a recognition of its scientific progress. The win highlights the involvement of veteran biotech executives Clive Meanwell…
    Endpoints · 29d agoPositive↗ source
  • Travere names former Amicus CEO Bradley Campbell as new leader; Roche eyes board seat for ex‑Takeda chief Alex Hoffman
    Travere Therapeutics announced that its long‑time chief executive Eric Dube will step down at the start of December, ending an almost eight‑year tenure. The board has selected Bradley Campbell, wh…
    Endpoints · 29d agoNeutral↗ source
← prev
page 43 of 208
next →
95
globenewswire health73
fda press55
Ophthalmology883
Endocrinology & Metabolism699
Pain678
Nephrology676
Novo signs development deal with Swedish biotech Nanexa to license long-acting delivery technology
Novo Nordisk has entered a new development agreement with the Swedish biotech Nanexa. Under the pact, Nanexa will license its long-acting drug delivery platform to Novo, expanding the larger compa…
Endpoints · 29d agoDealNeutral↗ source
  • Experts say measles death counts are muddled by 'with' vs 'of' debate
    Public health scientists note that Pennsylvania reported two measles‑related deaths in August, but the county coroner described one infant as having died "with" measles rather than "from" the disea…
    STAT · 29d agoNeutral↗ source
  • Legend's five-year data suggests Carvykti could be a cure; Addex, Indivior split
    Plus news about Amberstone, Henlius and Boehringer Ingelheim. Legend adds to argument for Carvykti as a cure: J&J and Legend Biotech said Friday that 10 of 20 relapsed/refractory multiple myeloma p…
    Endpoints · 29d agoNeutral↗ source
  • Rakuten Medical appoints Hassan Danesi as chief medical officer, coming from Coherus Biosciences
    Rakuten Medical announced that Hassan Danesi will join the company as its new chief medical officer. The appointment was disclosed in a recent industry column. Danesi previously served as vice pre…
    STAT · 29d agoNeutral↗ source
  • Opinion: RFK Jr.’s use of the National Center for Health Statistics will add confusion to measles deaths count
    “A discrepancy between how federal and state public health officials determine measles deaths will only increase public confusion,” write Denys T. Lau and Jennifer D. Schoendorf.
    STAT · 29d agoNeutral↗ source
  • K2 Therapeutics seeks to blend China’s speed with global expertise after winning Endpoints 2026 award
    K2 Therapeutics, a small drug development company, was named the winner of the Endpoints 2026 award. The company said it will try to combine the rapid development pace found in China with its own…
    Endpoints · 29d agoNeutral↗ source
  • Federal judge overturns key disability protection law
    A federal judge has reversed a longstanding disability protection ruling, reducing the legal safeguards that favored community-based living over institutional care. The Justice Department had anno…
    STAT · 29d agoRegulatoryNegative↗ source
  • Opinion: FDA commissioner nominee Heidi Overton is ignoring the science on abortion drug
    “With this latest appointment, mifepristone has a new boss but an old problem,” writes Julie F. Kay, founder and CEO of Reproductive Futures.
    STAT · 29d ago↗ source
  • STAT+: Pharmalittle: We’re reading about a reticent FDA commish nominee, a Novo deal, and more
    President Trump’s nominee to lead the FDA was grilled by senators on hot button topics like China, vaccines, and abortion access
    STAT · 29d ago↗ source
  • Alnylam alumni lead RNAi biotech City Therapeutics to IPO filing
    Biotechs are rushing into the IPO queue. City Therapeutics submitted its public pitch late Thursday, the same night ADARx Pharmaceuticals priced its $446 million Nasdaq debut. Kendall Square-based ...
    Endpoints · 29d ago↗ source
  • FDA approves Eli Lilly’s weekly insulin Onswik for U.S. patients, expanding competition with Novo
    The U.S. Food and Drug Administration has cleared Eli Lilly’s weekly insulin product, Onswik, for use in American patients. This marks the drug’s fourth global approval after earlier clearances in…
    BioSpace · 1mo agoApprovalPositive↗ source
  • Kyverna reports one-year mobility gains and safety for CAR-T miv-cel in stiff-person syndrome, bolstering FDA filing plans
    Kyverna Therapeutics presented data from its Phase 2 KYSA-8 trial of miv-cel, a CAR-T therapy aimed at stiff-person syndrome (SPS). The study followed 26 patients for one year. At the one-year mar…
    BioSpace · 1mo agoPositive readoutPositive↗ source
  • Acadia misses mark in Alzheimer’s but concludes phase 3 ‘absolutely worth’ pursuing
    Acadia Pharmaceuticals’ phase 2 Alzheimer’s disease trial has missed its primary endpoint, but the company and analysts alike saw enough encouraging signals to support the continuation of a phase 3…
    Fierce Biotech · 1mo agoNegative readoutNegative↗ source
  • Heidi Overton, a New Mexico-born physician, nominated as FDA commissioner
    Heidi Overton grew up in Gallup, New Mexico, and as a college freshman expressed a desire to become a doctor and return to her small hometown. Her early ambition was highlighted in a 2007 intervie…
    STAT · 1mo agoRegulatoryPositive↗ source
  • FDA advisory panel finds Grail's Galleri multicancer blood test benefits outweigh risks
    A Food and Drug Administration advisory panel voted 7-2, with one abstention, to conclude that the probable benefits of Grail's Galleri multicancer blood test outweigh its risks. The panel unanimou…
    BioPharma Dive · 29d agoRegulatoryPositive↗ source
  • Roche signs up to $2 billion partnership with Atavistik to develop cardiometabolic drugs
    Roche announced a partnership with Atavistik Bio, a biotech focused on hematology, to pursue new small-molecule treatments for cardiovascular, renal and metabolic conditions. The agreement provide…
    BioSpace · 1mo agoDealPositive↗ source
  • Eli Lilly earmarks up to $3.25 billion for partnership with InnoCare Pharma
    Eli Lilly announced an upfront payment of $100 million to Beijing‑based InnoCare Pharma to start work on drug candidates for five targets that have critical unmet medical needs. The agreement also…
    BioSpace · 1mo agoDealNeutral↗ source
  • Radioligand therapy gains momentum as experts discuss expanding patient impact
    In a recent episode of the Denatured podcast presented by Curium, host Jennifer Smith-Parker spoke with Mike Patterson, CEO North America, and Sabine Brookman-May, Vice President and Head of Global…
    BioSpace · 1mo agoPositive↗ source
  • Henlius Biotech signs $440 million deal with Amberstone to develop T-cell engagers
    Henlius Biotech, a subsidiary of Fosun Pharma, announced a licensing agreement with California‑based Amberstone Biosciences valued at up to $440 million. The partnership will focus on creating anti…
    Fierce Biotech · 1mo agoDealPositive↗ source
  • Eli Lilly partners with China’s InnoCare on drug development deal worth up to $3.35 billion
    Eli Lilly has signed a partnership agreement with Beijing-based InnoCare to co-develop new medicines. InnoCare will apply its internal drug discovery platform while Lilly will contribute its devel…
    Endpoints · 1mo agoDealPositive↗ source
  • Roche signs $2 billion deal with Atavistik to discover allosteric cardiovascular-renal-metabolic drugs
    Roche announced a partnership with Cambridge-based biotech Atavistik Bio to develop allosteric small-molecule therapies for cardiovascular, renal and metabolic diseases. The agreement includes an u…
    Fierce Biotech · 1mo agoDealPositive↗ source
  • Eli Lilly commits $100M upfront in new five-target partnership with China's InnoCare
    Eli Lilly has agreed to pay $100 million upfront and in the near term to Chinese biotech InnoCare Pharma as part of a five‑target drug discovery partnership. The agreement also provides for up to $…
    Fierce Biotech · 1mo agoDealPositive↗ source
  • FDA nominee Heidi Overton avoids taking positions in Senate hearing on vaccines, China and abortion
    Heidi Overton, President Trump’s pick to lead the Food and Drug Administration, appeared before the Senate health committee for a two hour hearing. Senators focused their questions on China, vaccin…
    STAT · 1mo agoRegulatoryNegative↗ source